Literature DB >> 19559878

Development of an automatic solid phase extraction and liquid chromatography mass spectrometry method by using a monolithic column for the analysis of Cyclosporin A in human plasma.

Covadonga Alvarez1, Irving W Wainer.   

Abstract

A sensitive and specific and automated liquid chromatography-electrospray mass spectrometric (LC-ESI-MS) assay for the quantification of Cyclosporin A in human plasma was developed. Following a simple protein precipitation step, the supernatant was extracted on-line and directly injected into the system LC-ESI-MS. A relatively new type of monolithic column consisting of a silica rod with bimodal pore structure was used to achieve a retention time of 2.4 min with a very low backpressure at a flow rate of 1 ml/min. The assay was linear from 0.050 to 1.000 microg/ml. The mean recovery was 91%. The mean inter-day and intra-day precisions were 1.85% and 2.83%, respectively. The combination of the automated solid phase extraction and the low retention time achieved with this columns increase the throughput and decrease the time of analysis of each sample. This technology is useful in order to improve the efficiency of the bioanalytical studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19559878      PMCID: PMC2704474          DOI: 10.1016/j.talanta.2009.03.054

Source DB:  PubMed          Journal:  Talanta        ISSN: 0039-9140            Impact factor:   6.057


  13 in total

1.  New approaches to cyclosporine monitoring raise further concerns about analytical techniques.

Authors:  D W Holt; A Johnston; B D Kahan; R G Morris; M Oellerich; L M Shaw
Journal:  Clin Chem       Date:  2000-06       Impact factor: 8.327

2.  Octadecylsilylated porous silica rods as separation media for reversed-phase liquid chromatography.

Authors:  H Minakuchi; K Nakanishi; N Soga; N Ishizuka; N Tanaka
Journal:  Anal Chem       Date:  1996-10-01       Impact factor: 6.986

3.  Optimized analytical method for cyclosporin A by high-performance liquid chromatography-electrospray ionization mass spectrometry.

Authors:  L Zhou; D Tan; J Theng; L Lim; Y P Liu; K W Lam
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-04-15

4.  Separation of cyclosporins by high-performance liquid chromatography and mass spectrometric study of cyclosporin metabolites.

Authors:  J Tuominen; T Suortti; K Ishikawa; J Lundell; Y Koga
Journal:  Rapid Commun Mass Spectrom       Date:  1998       Impact factor: 2.419

5.  Evaluation and comparison of therapeutic monitoring of whole-blood levels of cyclosporin A and its metabolites in renal transplantation by HPLC and RIA methods.

Authors:  K Safarcík; H Brozmanová; V Bartos; A Jegorov; M Grundmann
Journal:  Clin Chim Acta       Date:  2001-08-20       Impact factor: 3.786

6.  Effect of skeleton size on the performance of octadecylsilylated continuous porous silica columns in reversed-phase liquid chromatography.

Authors:  H Minakuchi; K Nakanishi; N Soga; N Ishizuka; N Tanaka
Journal:  J Chromatogr A       Date:  1997-02-21       Impact factor: 4.759

7.  The potential replacement of HPLC by 125I-RIA for the characterization of cyclosporin A: a bioavailability study after oral administration in healthy human subjects.

Authors:  Y J Lee; S J Chung; C K Shim
Journal:  J Pharm Biomed Anal       Date:  2000-02       Impact factor: 3.935

8.  Cyclosporine kinetics in renal transplantation.

Authors:  R J Ptachcinski; R Venkataramanan; J T Rosenthal; G J Burckart; R J Taylor; T R Hakala
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

Review 9.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

10.  A specific method for the measurement of cyclosporin A in human whole blood by liquid chromatography-tandem mass spectrometry.

Authors:  J Simpson; Q Zhang; P Ozaeta; H Aboleneen
Journal:  Ther Drug Monit       Date:  1998-06       Impact factor: 3.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.